Certara, Inc. provides advanced software solutions and technology-driven services, specializing in biosimulation throughout the entire drug development lifecycle. From initial drug discovery ...
Certara, Inc. is a global biosimulation company founded in 2008 and headquartered in Radnor, Pennsylvania. It provides advanced software and technology-driven services to optimize drug development across the entire lifecycle, from discovery and preclinical research to clinical trials, regulatory submissions, and market access. The company's core mission is to accelerate the delivery of new medicines to patients by transforming traditional processes with biosimulation software and expertise. Its portfolio includes mechanistic and empirical biosimulation, strategic guidance for drug development and regulatory affairs, clinical pharmacology, model-based meta-analysis, regulatory writing and communications, and market access consultation. Certara's software platforms cover PK/PD biosimulation, data standardization, regulatory submission authoring, and market access communication. The company serves biopharmaceutical firms, academic institutions, and government organizations. With over 1,515 employees and operations in more than 30 countries, Certara maintains a significant global presence. Key financial metrics indicate a market cap of approximately $1.28 billion, with a focus on revenue generation despite recent net losses. The founding CEO was Jon Resnick, who has been leading the company toward innovation in model-informed drug development. Certara is publicly traded on NASDAQ under the symbol CERT and continues to expand its technological capabilities, as evidenced by initiatives like Certara.AI, which applies artificial intelligence to drug discovery and regulatory processes.
